Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
ACS Chemical Neuroscience|October 15, 2016
Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead OptimizationArup K Ghose, Gregory R Ott, Robert L HudkinsDrug Discovery Today|November 30, 2006
Knowledge-based chemoinformatic approaches to drug discoveryArup K Ghose, Torsten Herbertz, Joseph M Salvino, et al.ACS Chemical Neuroscience|January 24, 2012
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug DiscoveryArup K Ghose, Torsten Herbertz, Robert L Hudkins, et al.Bioorganic & Medicinal Chemistry Letters|November 9, 2011
Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy groupRabindranath Tripathy, Robert J McHugh, Arup K Ghose, et al.Biochemistry|March 3, 2009
ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitorsLihui Lu, Arup K Ghose, Matthew R Quail, et al.Journal of Medicinal Chemistry|December 17, 2011
Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocyclesHenry J Breslin, Brandon M Lane, Gregory R Ott, et al.Bioorganic & Medicinal Chemistry|May 21, 2010
Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinaseKaren L Milkiewicz, Linda R Weinberg, Mark S Albom, et al.Journal of Medicinal Chemistry|May 9, 2012
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinaseDiane E Gingrich, Joseph G Lisko, Matthew A Curry, et al.Journal of Medicinal Chemistry|August 24, 2011
2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activityGregory R Ott, Gregory J Wells, Tho V Thieu, et al.Journal of Medicinal Chemistry|August 17, 2016
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)Gregory R Ott, Mangeng Cheng, Keith S Learn, et al.Pageof 2